Cassava RefocusALZ


The purpose of this study is to learn more about the use of the study drug, simufilam, for the treatment of Alzheimer’s disease. We want to test that it is safe and to find out whether it can slow down the advance of Alzheimer’s disease.

General Eligibility

  • Diagnosis of mild or moderate AD
  • 50-87 years old (inclusive)
  • Has a trial partner to come to visits

Primary Investigator: Malgorzata Franczak, MD

Status: Currently Enrolling

Sub Category